Leadership and governance Recent governance refresh including appointment of new CFO and Non-Executive Director/Chair, plus director change in Oct 2026. Opportunity to engage with new leadership to discuss strategic partnerships, licensing, and potential advisory or collaboration deals tied to growth plans and governance alignment.

Strategic review Independent strategic review commissioned to enhance shareholder value signals openness to partnerships, acquisitions, or licensing arrangements. Proactive outreach to present collaboration opportunities, joint development programs, or commercialization partnerships could align with their strategic refresh.

GMP manufacturing momentum Partnership with Viral Vector Manufacturing Facility to boost GMP-grade lentiviral vector production indicates capacity-building for cell therapy programs. Target discussions around scalable vector supply, tech transfer, or co-development manufacturing agreements.

Funding runway Recent $2.5M R&D funding and ongoing government incentives suggest a focus on advancing clinical programs while seeking capital-efficient partnerships. Propose co-funding opportunities, grant-aligned programs, or cost-sharing collaborations to accelerate development.

Clinical-stage focus As Australia’s only clinical-stage cell therapy biotechnology company and ASX leader, there is strong positioning for regional partnerships, supply agreements, and investor-backed joint ventures to accelerate clinical work, manufacturing scale, and eventual commercialization in Asia-Pacific markets.